A 23-year-old male shared his 6-month hair transformation using Dutasteride, oral Minoxidil, ketoconazole shampoo, vitamin D, gym, cardio, and dermastamping. He reported significant hair maintenance and no side effects.
Dutasteride takes 1-3 months to affect scalp DHT levels, not just a week. The prostate absorbs Dutasteride faster than the scalp due to different vascular networks and enzyme densities.
A user speculates that a fast metabolism might affect the effectiveness of dutasteride for hair loss. Another user argues that drug response is unrelated to metabolism speed.
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.
A dutasteride simulator predicts that daily 0.5 mg dosing results in higher DHT suppression compared to less frequent dosing. Twice-weekly dutasteride may be as effective as finasteride 5 mg, providing a balance between efficacy and ease of use.
RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.
A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.
The conversation discusses the use of RU58841 for hair loss, focusing on its side effects, standardization issues, and user experiences. The user also inquires about the use of other treatments like minoxidil, finasteride, and microneedling.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
The user is experiencing hair thinning despite using Dutasteride and Finasteride and is considering adding Minoxidil. Suggestions include increasing the Dutasteride dose, checking for health issues, and considering a hair transplant.
A user reported significant hair improvement after one month of using dutasteride and oral minoxidil. Others expressed skepticism, attributing perceived changes to lighting and styling, and debated the effectiveness and risks of these treatments.
The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.
A user received Kintor’s KX-826/Pyrilutamide and shared initial impressions, noting concerns about the product's labeling and marketing. Other users discussed the legitimacy of the product, its effectiveness, and compared it to other treatments like Minoxidil and Finasteride.
The conversation discusses switching from finasteride to dutasteride for hair loss treatment, with mixed experiences regarding shedding and effectiveness. Some users also mention using minoxidil and RU58841 alongside these treatments.
This conversation is about how topical treatments for hair loss, such as Minoxidil and Finasteride, can be replaced by drinking oral versions of the same medications to achieve better results with less hassle. Some users have already been doing this with positive results.
The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.
Dutasteride is often preferred over Finasteride due to fewer side effects and better hair regrowth. Initial side effects like lowered libido may occur but typically diminish over time.
Increasing finasteride dosage can cause significant hair shedding initially. Users suggest adding minoxidil or switching to dutasteride for better results.
A user stopped finasteride due to side effects and rapid hair loss, considering a hair system. Others suggested alternatives like dutasteride, minoxidil, and topical finasteride.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The conversation discusses the potential benefits of sublingual minoxidil for hair loss treatment. It suggests that sublingual minoxidil, which bypasses the liver, may have fewer side effects, greater bioavailability, and could be more effective than oral minoxidil.
The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.
Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.
Topical dutasteride is suggested as a low side-effect treatment for hair loss, with a proposed dose of 0.025% 1ml/day. It is considered better than finasteride due to its even inhibition of DHT isoforms and lower systemic absorption.
Topical Finasteride doesn't directly reduce 5ar enzyme on scalp and has the same mechanism as oral, needing to go through the liver. Users debate the accuracy of this information and discuss various studies and experiences.
